Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Anti-MDA5 autoantibodies are critical biomarkers for dermatomyositis (DM), amyopathic dermatomyositis (CADM), and polymyositis (PM), particularly in identifying patients at risk of rapidly progressive interstitial lung disease (RP-ILD). Early detection of these autoantibodies is essential to improve patient outcomes, as delayed diagnosis often leads to poor prognoses. Currently, radioimmunoassay is the gold standard for detecting anti-MDA5, but its use is limited by high costs, lengthy procedures, and the need for specialized expertise. Additionally, the blot test, a widely used clinical tool, exhibits a high false-positive rate for MDA5 autoantibodies, potentially compromising diagnostic accuracy. To address these limitations, we propose a non-radioactive, highly sensitive, and standardized confirmatory testing method using Immunocytochemistry (ICC). This protocol involves treating HeLa cells with an MDA5 construct, permeabilizing the cells with Triton X-100 to facilitate binding of primary anti-MDA5 autoantibodies, and detecting bound antibodies using enzyme-conjugated secondary antibodies (e.g., horseradish peroxidase) with DAB chromogen for microscopy imaging. ICC offers a practical, cost-effective, and high-sensitivity approach for visualizing anti-MDA5 autoantibodies within cellular structures. By integrating ICC as a supplementary confirmatory procedure, this study aims to enhance the reliability of anti-MDA5 detection, thereby improving diagnostic and prognostic strategies for RP-ILD in DM, CADM, and PM patients.